EMA Expands Meningococcal and RSV Protection for Infants

The European Medicines Agency's human medicines committee recommended lower minimum ages for Bexsero and extended use of Enflonsia for at-risk children.

Updated on Nov. 17, 2026 in Children’s Health

Photograph of a clear glass vial and a plain syringe on a pale clinical surface beside a folded white blanket, in soft daylight.
The European Medicines Agency's human medicines committee recommended lowering the minimum age for Bexsero to six weeks and extending Enflonsia use to children up to 24 months. AI Illustration. Upload story photo >

Live Poll

Would you feel confident having your infant receive a newly expanded RSV or meningitis-prevention shot?

The CHMP recommended lowering the minimum age for Bexsero from 2 months to 6 weeks and extending Enflonsia use to children up to 24 months who remain vulnerable to severe RSV disease. The recommendations expand pediatric protection against meningococcal group B disease and severe RSV infection.

Why it matters

Serogroup B became the leading cause of invasive meningococcal disease in Europe after serogroup C vaccines were introduced, and invasive infections can cause serious conditions such as meningitis and septicemia. RSV accounts for an estimated 2.2 million hospitalizations annually worldwide among children younger than 1 year, making earlier and longer protection a significant public health consideration.

The SMART trial enrolled 997 first-season infants and 276 second-season children, with a 7.3% cumulative incidence of medically attended RSV lower respiratory infection through day 180 in the second season. The second-season comparator outcomes and the updated product labeling details remain to be detailed in the forthcoming Summary of Product Characteristics.

The players

European Medicines Agency

The EU regulatory agency responsible for the scientific evaluation of medicines, whose committee issued the recommendations.

GlaxoSmithKline Vaccines

The vaccine manufacturer responsible for Bexsero, a meningococcal group B vaccine.

Merck Sharp & Dohme Limited

The pharmaceutical company associated with Enflonsia, the RSV monoclonal antibody discussed in the recommendations.

The details

The CHMP recommended that Bexsero's minimum age drop from 2 months to 6 weeks, and that Enflonsia use extend to children up to 24 months who remain vulnerable through their second RSV season. Enflonsia, a long-acting monoclonal antibody that binds the RSV fusion protein, is given as a single 105-mg intramuscular thigh injection for first-season prevention.

Timeline

  1. Recommendation issued on November 17, 2026, by the European Medicines Agency's CHMP.

  2. Following European Commission approval, updated Summary of Product Characteristics documents will provide expanded-use guidance.

Health Landscape

Serogroup B became Europe's leading cause of invasive meningococcal disease after serogroup C vaccines were introduced, and this recommendation extends Bexsero protection to younger infants in response. The RSV component similarly targets a documented burden of roughly 2.2 million annual hospitalizations among children under one worldwide.

Parents of infants in the affected age ranges may see the Bexsero minimum age lowered to 6 weeks and Enflonsia offered for a second RSV season, subject to European Commission approval and updated product documentation. Families should consult their pediatric providers about how these changes apply to their child's vaccination and prevention schedule.

The takeaway

Expanded eligibility for infant meningococcal and RSV protection reflects the growing emphasis on early prevention for the youngest and most vulnerable children. Parents can discuss timing and eligibility with their child's healthcare provider as updated labeling becomes available.

Further reading

Explore more on Children's Health for context on infant vaccination and respiratory illness.

Source note: This article includes information reported by Medscape.

Live Poll

Would you feel confident having your infant receive a newly expanded RSV or meningitis-prevention shot?